NGS-SA SARS-CoV-2 Sequencing Update

5 August 2021

Network for Genomic Surveillance South Africa (NGS-SA)
























Network for Genomic Surveillance in South Africa (NGS-SA)



Msomi N, Mlisana K, et al. Lancet Microbe 2020























The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 5 August at 09h09



Data license: https://www.gisaid.org/registration/terms-of-use/

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101

Variants of Concern (VOC)


WHO label	Pango lineages	GISAID clade	Nextstrain clade	Additional amino acid changes monitored*	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY	20I (V1)	+S:484K +S:452R	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351 B.1.351.2 B.1.351.3	GH/501Y.V2	20H (V2)	+S:L18F	South Africa, May-2020	18-Dec-2020
Gamma	P.1 P.1.1 P.1.2	GR/501Y.V3	20J (V3)	+S:681H	Brazil, Nov-2020	11-Jan-2021
Delta	B.1.617.2 AY.1 AY.2	G/478K.V1	21A	+S:417N	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 5 August 2021

^{*}Notable spike (S) amino acid changes under monitoring, which are currently reported in a minority of sequenced samples


Currently designated Variants of Interest (VOI)

WHO label	Pango lineages	GISAID clade	Nextstrain clade	Earliest documented samples	Date of designation
Eta	B.1.525	G/484K.V3	21D	Multiple countries, Dec-2020	17-Mar-2021
lota	B.1.526	GH/253G.V1	21F	United States of America, Nov-2020	24-Mar-2021
Kappa	B.1.617.1	G/452R.V3	21B	India, Oct-2020	4-Apr-2021
Lambda	C.37	GR/452Q.V1	21G	Peru, Dec-2020	14-Jun-2021




^{*}This represents the cleaned, de-duplicated dataset of unique sequences. This dataset will be used for all further figures.

GISAID genomes vs total cases, 2020 and 2021 (N=13 436)



All provinces, apart from GP, WC and KZN, have a similar percentage of overall cases as overall sequenced genomes.


South African genomes submitted per sequencing lab, 2020 and 2021 (N=13 436)



*NGS-SA laboratories

Multiple labs from NGS-SA are contributing to the sequencing effort. Sequencing efforts have increased with the third wave.

Distribution and number of clades in South Africa, 2021 (N=7 396)




Sequencing data ending epi week 30 (ending 31 July 2021)

Currently in epi week 31 (ending 7 August 2021)


Alpha, Delta and Eta variant frequency increasing as of the beginning of May (epi-week 18, 2 May). Delta becoming dominant by end of June (341/438, 78% in week 24; 424/486, 87% in week 25; 532/578, 92% in week 26; 328/350, 94% in week 27; 173/182, 95% in week 28 – excludes unassigned sequences)

Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in May, June and July 2021 sequences, South Africa




Beta variant dominated in May, while the Delta variant dominated in June and July in South Africa

Genomes sequenced from specimens collected in May – July 2021 (epiweeks 18 – 31) from KwaZulu-Natal, Gauteng, Western Cape Provinces




Beta dominates in all provinces in May, however following its detection in week 18, Delta rapidly begins to dominate in all three provinces by mid-June

Genomes sequenced from specimens collected in May – July 2021 (epiweeks 18 – 31) from Eastern Cape, Limpopo and North-West Provinces




Genomes sequenced from specimens collected in May – July 2021 (epiweeks 18 – 31) from Free State, Mpumalanga and Northern Cape Provinces



Gauteng Province, 2021, n = 2507


20H (Beta, V2)



KwaZulu-Natal Province, 2021, n = 1202

21A (Delta)


20H (Beta, V2)



Western Cape Province, 2021, n = 1085

20H (Beta, V2)

21A (Delta)




20D (C.1.2)

Eastern Cape Province, 2021, n = 738

21A (Delta)

20H (Beta, V2)




20D (C.1.2)

Limpopo Province, 2021, n = 485

21A (Delta)

20H (Beta, V2)




20D (C.1.2)

Mpumalanga Province, 2021, n = 301

21A (Delta)

20H (Beta, V2)




20D (C.1.2)

Northern Cape Province, 2021, n = 355

20H (Beta, V2)

21A (Delta)




20D (C.1.2)


North West Province, 2021, n = 334

21A (Delta)


20H (Beta, V2)



Free State Province, 2021, n = 309




C.1.2 (n=43 in SA) in May – July 2021 by epiweek



C.1.2 has now been detected in six provinces. The majority of samples have been detected in Gauteng (n=30), followed by Limpopo (n=5) and Mpumalanga (n=5).

C.1.2 (n=43 in SA) in May – July 2021 by epiweek



C.1.2 has now been detected in six provinces. KwaZulu-Natal, the Eastern Cape and the Western Cape have only had one sample each detected so far.

Summary

- In June, Delta increased and dominated in most provinces with recent data available.
- Delta remained dominant in July, but additional sequencing data are required to confirm these proportions in all provinces.
- With the dominance of Delta, overall diversity of SARS-CoV-2 decreased, as evidenced by fewer lineages detected.
- Mutated C.1 lineage has been given designation C.1.2 by Pangolin¹ and has now been detected in six provinces in South Africa: Eastern Cape, Gauteng, Mpumalanga, Limpopo, KwaZulu-Natal, Western Cape.

Multi-institute, multi-disciplinary NGS team

Network for Genomic Surveillance in South Africa (NGS-SA) WANTIONAL RETITUTE POR COMMUNICURE CORRECT (NICE) WHITE A MALS WIND STRUCTURE STATE (NICE) WHITE A MALS WHITE STATE (NICE) WHITE A MALS WHITE STATE (NICE) Supported by the DSI and the SA MRC Miscrib Microbe 2020 Supported by the DSI and the SA MRC Miscrib Microbe 2020 WIND STRUCTURE STATE (NICE) Supported by the DSI and the SA MRC Miscrib Microbe 2020 WIND STRUCTURE STATE (NICE) Supported by the DSI and the SA MRC Miscrib Microbe 2020 WIND STRUCTURE STATE (NICE) Supported by the DSI and the SA MRC Miscrib Microbe 2020 WIND STRUCTURE STATE (NICE) Supported by the DSI and the SA MRC Miscrib Microbe 2020 WIND STRUCTURE STATE (NICE) Supported by the DSI and the SA MRC Miscrib Microbe 2020 WIND STRUCTURE STATE (NICE) WIND STRUCTURE STATE (NICE) WIND STRUCTURE STATE (NICE) SUPPORTED STATE (NICE) WIND STRUCTURE STATE (NIC

Contributors of samples to NICD:

Adriano Mendes
Allison J. Glass
Amy Strydom
Andries Dreyer
Christa Viljoen
Eddie Silberbauer
Elias Bereda
Eugene Elliot
Florah Mnyameni
Florette K. Treurnicht
Gloria Selabe

Greta Hoyland Sir
Howard Newman Te
Jeannette Wadula Warianne Subramoney Zir
Lia Rotherham
Marianne Wolfaardt
Marietjie Venter
Michaela Davis
Oluwakemi Laguda-Akingba

Simnikiwe Mayaphi Terry Marshall Warren Lowman Zinhle Makatini











Riaan Writes

Shareef Abrahams





















University of Cape Town, NHLS & WCG



NHLS-UCT

Carolyn Williamson Nei-yuan Hsiao Diana Hardie Kruger Marais Stephen Korsman Ziyaad Valley-Omar







UCT, IDM and CIDRI-Africa

Deelan Doolabh
Arash Iranzadeh
Lynn Tyers
Innocent Mudau
Nokuzola Mbhele
Fezokuhle Khumalo
Thabang Serakge
Bruna Galvão
Arghavan Alisoltani
(U. California)

Robert Wilkinson Darren Martin Nicola Mulder Wendy Burgers Ntobeko Ntusi Rageema Joseph Sean Wasserman Linda Boloko



WCG-UCT

Mary-Anne Davies Hannah Hussey Andrew Boulle Masudah Paleker Theuns Jacobs Erna Morden



Tulio de Oliveira (PI)

Richard Lessells Wolfgang Prieser Jennifer Giandhari Eduan Wilkinson Houriiyah Tegally

Koleka Mlisana

San James

Jinal Bhiman

Penny Moore

Anne von Gottberg
Dominique Goedhals

Susan Engelbrecht

Tongai Maponga

Nokukhanya Msomi

Glenda Gray

Glaudina Loots

Nigel Garret

Salim Abdool Karim

Funding / Support











UFS Acknowledgements

- Dominique Goedhals
- Armand Bester
- Martin Nyaga
- Peter Mwangi
- Emmanuel Ogunbayo
- Milton Mogotsi
- Makgotso Maotoana
- Lutfiyya Mahomed

NHLS Division of Virology:

- Sabeehah Vawda
- Felicity Burt
- Thokozani Mkhize
- Diagnostic laboratory staff





NICD Acknowledgements

- Thabo Mohale
- Daniel Amoako
- Cathrine Scheepers
- Josie Everatt
- Boitshoko Mahlangu
- Noxolo Ntuli
- Anele Mnguni
- Amelia Buys
- Cardia Fourie
- Noluthando Duma
- Linda de Gouveia
- Jackie Kleynhans
- Nicole Wolter
- Zamantungwa Khumalo
- Annie Chan
- Morne du Plessis
- Constantinos Kurt
 Wibmer

- Thandeka Moyo
- Tandile Hermanus
- Frances Ayres
- Zanele Molaudzi
- Bronwen Lambson
- Tandile Hermanus
- Sibongile Walaza
- Mignon du Plessis
- Stefano Tempia
- CRDM lab and epi staff
- Mvuyo Makhasi
- Brent Oosthuysen
- Susan Meiring
- Mashudu Madzivhandila
- Prudence Kgagudi
- Mushal Allam
- NICD SARS-CoV-2 Sequencing Group

- Stanford Kwenda
- Phillip Senzo Mtshali
- Ranmini Kularatne
- Arshad Ismail
- Penny Moore
- Anne von Gottberg
- Cheryl Cohen
- Lynn Morris
- Jinal Bhiman
- Erica Anderson-Nissen
- Anneta Naidoo
- Raymond Rott
- Simon Travers (Hyrax Biosciences)

NICD COVID-19 response team COVID Incident Management Team

















Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
 - all ages
 - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to NGS-SA sequencing laboratories on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
 - All positives samples should be sent every week (NGS-SA will perform random sampling as described below) OR
 - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)